Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

UK authorities OK increased gap between Pfizer COVID-19 vaccine doses

By Brian Buntz | December 31, 2020

NHSThe National Health Service in the U.K. is increasing the maximum interval between shots for recipients of the Pfizer (NYSE:PFE) and BioNTech (NSDQ:BNTX) vaccine to 12 weeks. In a letter to hospitals, NHS advised that patients scheduled to receive the second dose of the vaccine on Jan. 4 should receive it nine weeks later. 

The developers of the vaccine intended for doses to be delivered 21 days apart. Pfizer and BioNTech, however, tested administering the second dose up to 42 days after the first vaccination. Roughly 80% of the Phase 3 trial participants received the second dose within 10 weeks after the first.  

U.K. recipients of the first dose of vaccine from AstraZeneca (LON:AZN) and Oxford University must also wait up to 12 weeks for the second dose.  

While none of the vaccine developers mentioned above have thoroughly tested the 12-week interval, NHS has concluded the decision will have the most significant impact on mortality.  

Pfizer said in a statement that the “safety and efficacy of the vaccine has not been evaluated on different dosing schedules as the majority of trial participants received the second dose within the window specified in the study design.” 

The company also concluded that regulators study the impact of such modified dosing schedules on immunity to maximize protection. 

The British Medical Association (BMA) criticized the revised dosing schedule. In a statement, the group concluded that asking general practitioners to “rebook appointments of tens of thousands of elderly and vulnerable patients, due to get their second dose of the Covid-19 vaccination in a few days’ time, is unreasonable and totally unfair.”   


Filed Under: clinical trials, Drug Discovery, Infectious Disease
Tagged With: AstraZeneca plc, BioNTech, coronavirus, covid-19, COVID-19 vaccine, COVID-19 vaccine trial, Pfizer
 

Tell Us What You Think! Cancel reply

You must be logged in to post a comment.

Related Articles Read More >

Bavarian Nordic
U.S. purchases more monkeypox vaccine doses from Bavarian Nordic
covid-19 vaccine
FDA backs COVID-19 boosters with BA.4/5 spike proteins for fall
Pfizer-BioNTech
Pfizer and BioNTech forge new COVID-19 vaccine deal with U.S. government
Icosavax
Icosavax shares positive early results for VLP vaccine candidate against RSV

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50